-
Gemtuzumab ozogamicin
- indication:For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy.
- pharmacologypharmacology:
- mechanism: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death.
- toxicity: The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder.
- absorprion:
- halflife:
- roouteelimination:
- volumedistribution:
- clearance: